MC-12, an annexin A1-based peptide, is effective in the treatment of experimental colitis

PLoS ONE

Volumn 7, Issue 7, 2012, Pages

  Ouyang, Nengtai ^a   Zhu, Caihua ^a   Zhou, Dingying ^a   Nie, Ting ^a   Go, Mae F ^b   Richards, Robert J ^a   Rigas, Basil ^a  

^a STONY BROOK UNIVERSITY   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; CYCLOOXYGENASE 2; CYTOSOLIC PHOSPHOLIPASE A2; GAMMA INTERFERON; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; LIPOCORTIN 1; MC 12; MYELOPEROXIDASE; PROSTAGLANDIN E2; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; COLITIS; CONTROLLED STUDY; DOWN REGULATION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MECHANISM; DRUG SCREENING; ENZYME ACTIVITY; EXPERIMENTAL STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCORING SYSTEM;

ANIMALS; ANNEXIN A1; CELL LINE; COLITIS; COLON; CYCLOOXYGENASE 2; CYTOKINES; DEXTRAN SULFATE; DINOPROSTONE; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INDUCTION; FEMALE; GROUP IV PHOSPHOLIPASES A2; HUMANS; INTESTINAL MUCOSA; MICE; NF-KAPPA B; OLIGOPEPTIDES; PEROXIDASE; TRINITROBENZENESULFONIC ACID;

MUS;

EID: 84864210628     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0041585     Document Type: Article

References (44)

1. Vatn MH, (2009) Natural history and complications of IBD. Curr Gastroenterol Rep 11: 481-487.
2. Mayer L, (2010) Evolving paradigms in the pathogenesis of IBD. J Gastroenterol 45: 9-16.
3. Szigethy E, McLafferty L, Goyal A, (2010) Inflammatory bowel disease. Child Adolesc Psychiatr Clin N Am 19: 301-318, ix.
4. Devlin SM, Panaccione R, (2009) Evolving inflammatory bowel disease treatment paradigms: top-down versus step-up. Gastroenterol Clin North Am 38: 577-594.
5. Benchimol EI, Seow CH, Steinhart AH, Griffiths AM, (2008) Traditional corticosteroids for induction of remission in Crohn's disease. Cochrane Database Syst Rev.
6. de Silva S, Devlin S, Panaccione R, (2010) Optimizing the safety of biologic therapy for IBD. Nat Rev Gastroenterol Hepatol 7: 93-101.
7. Campbell KJ, Perkins ND, (2006) Regulation of NF-kappaB function. Biochem Soc Symp pp. 165-180.
8. Zhang Z, Huang L, Zhao W, Rigas B, (2010) Annexin 1 induced by anti-inflammatory drugs binds to NF-kappaB and inhibits its activation: anticancer effects in vitro and in vivo. Cancer Res 70: 2379-2388.
9. Perretti M, D'Acquisto F, (2009) Annexin A1 and glucocorticoids as effectors of the resolution of inflammation. Nat Rev Immunol 9: 62-70.
10. Perretti M, Gavins FN, (2003) Annexin 1: an endogenous anti-inflammatory protein. News Physiol Sci 18: 60-64.
11. Wirtz S, Neurath MF, (2007) Mouse models of inflammatory bowel disease. Adv Drug Deliv Rev 59: 1073-1083.
12. Kawada M, Arihiro A, Mizoguchi E, (2007) Insights from advances in research of chemically induced experimental models of human inflammatory bowel disease. World J Gastroenterol 13: 5581-5593.
13. Roncucci L, Mora E, Mariani F, Bursi S, Pezzi A, et al. (2008) Myeloperoxidase-positive cell infiltration in colorectal carcinogenesis as indicator of colorectal cancer risk. Cancer Epidemiol Biomarkers Prev 17: 2291-2297.
14. Perez-Chacon G, Astudillo AM, Balgoma D, Balboa MA, Balsinde J, (2009) Control of free arachidonic acid levels by phospholipases A2 and lysophospholipid acyltransferases. Biochim Biophys Acta 1791: 1103-1113.
15. Haeggstrom JZ, Rinaldo-Matthis A, Wheelock CE, Wetterholm A, (2010) Advances in eicosanoid research, novel therapeutic implications. Biochem Biophys Res Commun 396: 135-139.
16. Gustafson-Svard C, Lilja I, Sjodahl R, Tagesson C, (1995) Cytosolic phospholipase A2 and cyclooxygenase-2 mediate release and metabolism of arachidonic acid in tumor necrosis factor-alpha-primed cultured intestinal epithelial cells (INT 407). Scand J Gastroenterol 30: 1000-1007.
17. Fantini MC, Pallone F, (2008) Cytokines: from gut inflammation to colorectal cancer. Curr Drug Targets 9: 375-380.
18. Sanchez-Munoz F, Dominguez-Lopez A, Yamamoto-Furusho JK, (2008) Role of cytokines in inflammatory bowel disease. World J Gastroenterol 14: 4280-4288.
19. Karin M, (2006) Nuclear factor-kappaB in cancer development and progression. Nature 441: 431-436.
20. Danese S, Mantovani A, (2010) Inflammatory bowel disease and intestinal cancer: a paradigm of the Yin-Yang interplay between inflammation and cancer. Oncogene 29: 3313-3323.
21. Atreya I, Atreya R, Neurath MF, (2008) NF-kappaB in inflammatory bowel disease. J Intern Med 263: 591-596.
22. Karrasch T, Jobin C, (2008) NF-kappaB and the intestine: friend or foe? Inflamm Bowel Dis 14: 114-124.
23. Andresen L, Jorgensen VL, Perner A, Hansen A, Eugen-Olsen J, et al. (2005) Activation of nuclear factor kappaB in colonic mucosa from patients with collagenous and ulcerative colitis. Gut 54: 503-509.
24. Takada Y, Ray N, Ikeda E, Kawaguchi T, Kuwahara M, et al. (2010) Fos proteins suppress dextran sulfate sodium-induced colitis through inhibition of NF-kappaB. J Immunol 184: 1014-1021.
25. Herfarth H, Brand K, Rath HC, Rogler G, Scholmerich J, et al. (2000) Nuclear factor-kappa B activity and intestinal inflammation in dextran sulphate sodium (DSS)-induced colitis in mice is suppressed by gliotoxin. Clin Exp Immunol 120: 59-65.
26. Marrero JA, Matkowskyj KA, Yung K, Hecht G, Benya RV, (2000) Dextran sulfate sodium-induced murine colitis activates NF-kappaB and increases galanin-1 receptor expression. Am J Physiol Gastrointest Liver Physiol 278: G797-804.
27. Bhattacharyya S, Dudeja PK, Tobacman JK, (2009) ROS, Hsp27, and IKKbeta mediate dextran sodium sulfate (DSS) activation of IkappaBa, NFkappaB, and IL-8. Inflamm Bowel Dis 15: 673-683.
28. Hendel J, Nielsen OH, (1997) Expression of cyclooxygenase-2 mRNA in active inflammatory bowel disease. Am J Gastroenterol 92: 1170-1173.
29. Paiotti AP, Miszputen SJ, Oshima CT, de Oliveira Costa H, Ribeiro DA, et al. (2009) Effect of COX-2 inhibitor after TNBS-induced colitis in Wistar rats. J Mol Histol 40: 317-324.
30. Tanaka K, Suemasu S, Ishihara T, Tasaka Y, Arai Y, et al. (2009) Inhibition of both COX-1 and COX-2 and resulting decrease in the level of prostaglandins E2 is responsible for non-steroidal anti-inflammatory drug (NSAID)-dependent exacerbation of colitis. Eur J Pharmacol 603: 120-132.
31. Kefalakes H, Stylianides TJ, Amanakis G, Kolios G, (2009) Exacerbation of inflammatory bowel diseases associated with the use of nonsteroidal anti-inflammatory drugs: myth or reality? Eur J Clin Pharmacol 65: 963-970.
32. Barros KV, Xavier RA, Abreu GG, Martinez CA, Ribeiro ML, et al. (2010) Soybean and fish oil mixture increases IL-10, protects against DNA damage and decreases colonic inflammation in rats with dextran sulfate sodium (DSS) colitis. Lipids Health Dis 9: 68.
33. Kim SW, Rhee HJ, Ko J, Kim YJ, Kim HG, et al. (2001) Inhibition of cytosolic phospholipase A2 by annexin I. Specific interaction model and mapping of the interaction site. J Biol Chem 276: 15712-15719.
34. Lim LH, Pervaiz S, (2007) Annexin 1: the new face of an old molecule. Faseb J 21: 968-975.
35. Peterson JW, Dickey WD, Saini SS, Gourley W, Klimpel GR, et al. (1996) Phospholipase A2 activating protein and idiopathic inflammatory bowel disease. Gut 39: 698-704.
36. Rogler G, Brand K, Vogl D, Page S, Hofmeister R, et al. (1998) Nuclear factor kappaB is activated in macrophages and epithelial cells of inflamed intestinal mucosa. Gastroenterology 115: 357-369.
37. Lee KM, Kang BS, Lee HL, Son SJ, Hwang SH, et al. (2004) Spinal NF-kB activation induces COX-2 upregulation and contributes to inflammatory pain hypersensitivity. Eur J Neurosci 19: 3375-3381.
38. Newton R, Kuitert LM, Bergmann M, Adcock IM, Barnes PJ, (1997) Evidence for involvement of NF-kappaB in the transcriptional control of COX-2 gene expression by IL-1beta. Biochem Biophys Res Commun 237: 28-32.
39. Clapper ML, Cooper HS, Chang WC, (2007) Dextran sulfate sodium-induced colitis-associated neoplasia: a promising model for the development of chemopreventive interventions. Acta Pharmacol Sin 28: 1450-1459.
40. Dieleman LA, Palmen MJ, Akol H, Bloemena E, Pena AS, et al. (1998) Chronic experimental colitis induced by dextran sulphate sodium (DSS) is characterized by Th1 and Th2 cytokines. Clin Exp Immunol 114: 385-391.
41. Moreels TG, Nieuwendijk RJ, De Man JG, De Winter BY, Herman AG, et al. (2004) Concurrent infection with Schistosoma mansoni attenuates inflammation induced changes in colonic morphology, cytokine levels, and smooth muscle contractility of trinitrobenzene sulphonic acid induced colitis in rats. Gut 53: 99-107.
42. Lin YZ, Yao SY, Veach RA, Torgerson TR, Hawiger J, (1995) Inhibition of nuclear translocation of transcription factor NF-kappa B by a synthetic peptide containing a cell membrane-permeable motif and nuclear localization sequence. J Biol Chem 270: 14255-14258.
43. Hori Y, Oda Y, Kiyoshima K, Yamada Y, Nakashima Y, et al. (2007) Oxidative stress and DNA hypermethylation status in renal cell carcinoma arising in patients on dialysis. J Pathol 212: 218-226.
44. Williams JL, Ji P, Ouyang N, Liu X, Rigas B, (2008) NO-donating aspirin inhibits the activation of NF-kappaB in human cancer cell lines and Min mice. Carcinogenesis 29: 390-397.